Next Phase Newsletter

A venture firm based in China has a multi-billion dollar fund and is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed fund based in the USA focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading European independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised three funds to date. The investments typically range from €5 million to €20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science investment arm of a global private equity has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide.

The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, the firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is specializing in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing medical devices, diagnostics tools and instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A listed pharmaceutical company in Asia with 5 Billion of assets under management is actively seeking global R&D partnerships and investment opportunities. Through over 2 decades of arduous efforts, it has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area.

The firm has focused interest in Traditional Chinese Medicine granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm invests across multiple funds, with each fund focused on a sector of strategic interest to the parent organization. The firm typically leads or co-leads rounds as a member of a syndicate of investors. The firm is actively seeking new investment opportunities across all funds.

The firm’s healthcare fund is looking for early stage companies working primarily within therapeutics. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat, and is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.